Page last updated: 2024-12-06

benzofurazan

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Benzofurazan is a heterocyclic compound with the molecular formula C6H4N2O. It is a colorless solid that is soluble in organic solvents. Benzofurazan is a versatile building block in organic synthesis, and it has been used to synthesize a wide range of heterocyclic compounds, including pharmaceuticals, pesticides, and dyes. The synthesis of benzofurazan typically involves the reaction of an o-nitroaniline with a reducing agent, such as sodium borohydride. The resulting benzofurazan can be further functionalized to create a variety of derivatives. Benzofurazan derivatives have been shown to possess a wide range of biological activities, including antibacterial, antifungal, anti-inflammatory, and anticancer activities. The unique electronic properties of benzofurazan make it an attractive target for the development of new functional materials. Benzofurazan derivatives have been used to synthesize organic semiconductors, sensors, and molecular switches. The study of benzofurazan and its derivatives is an active area of research in synthetic organic chemistry, medicinal chemistry, and materials science.'

benzofurazan: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID67501
CHEMBL ID4096941
CHEBI ID194617
SCHEMBL ID8380
MeSH IDM0073620

Synonyms (29)

Synonym
AC-13738
273-09-6
benzo-2,1,3-oxadiazole
benzofurazan
2,1,3-benzoxadiazole
inchi=1/c6h4n2o/c1-2-4-6-5(3-1)7-9-8-6/h1-4
benzofurazan, 97%
AKOS001580874
HMS1648J05
CHEBI:194617
A819003
benzo[c][1,2,5]oxadiazole
[2,1,3]benzoxadiazole
FT-0622699
SCHEMBL8380
W-202152
3,5-cyclohexadiene-1,2-dione, dioxime, furazan
2-oxa-1,3-diaza-2h-isoindene
2,1,3-benzoxadiazol
B4473
DTXSID00181742
mfcd00068064
AS-19794
CHEMBL4096941
2,1,3-benzooxadiazole
SY049993
n[2chloro4({[4(6methyl1,3benzothiazol2yl)phenyl]amino}sulfonyl)phenyl]acetamide
CS-W016582
EN300-97475

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
"An efficient, accurate and sensitive spectrofluorimetric method was developed for analysis of empagliflozin (EGF) in pure form, dosage form and human plasma."( New spectrofluorimetric analysis of empagliflozin in its tablets and human plasma using two level full factorial design.
Abdel Hamid, MA; Ahmed, HM; Batakoushy, HA; Omar, MA, 2020
)
0.56
" This approach was effectively employed to evaluate the content of 6-aminocaproic acid in laboratory prepared dosage form with average percentage recovery of 100."( Benzofurazan -based fluorophore for the spectrofluorimetric determination of 6-Aminocaproic acid: Application to spiked human plasma and urine.
Anwer, EF; Derayea, SM; Nour El-Deen, DAM; Omar, MA, 2022
)
2.16
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzoxadiazole
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1440295Inhibition of full length recombinant human His-tagged IDO1 expressed in mouse LLTC cells using L-tryptophan as substrate after 24 hrs2017European journal of medicinal chemistry, Jan-27, Volume: 126Discovery and evaluation of inhibitors to the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1): Probing the active site-inhibitor interactions.
AID1440277Inhibition of recombinant human IDO1 expressed in bacterial expression system at 400 uM using L-Tryptophan as substrate after 25 mins by fluorescence assay relative to control2017European journal of medicinal chemistry, Jan-27, Volume: 126Discovery and evaluation of inhibitors to the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1): Probing the active site-inhibitor interactions.
AID1440271Inhibition of recombinant human IDO1 S167A mutant expressed in Escherichia coli SG13009(pREP4) using L-Tryptophan as substrate after 25 mins by fluorescence assay2017European journal of medicinal chemistry, Jan-27, Volume: 126Discovery and evaluation of inhibitors to the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1): Probing the active site-inhibitor interactions.
AID1440296Cytotoxicity against mouse LLTC cells assessed as reduction in cell viability after 24 hrs by MTT assay2017European journal of medicinal chemistry, Jan-27, Volume: 126Discovery and evaluation of inhibitors to the immunosuppressive enzyme indoleamine 2,3-dioxygenase 1 (IDO1): Probing the active site-inhibitor interactions.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (48)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (8.33)18.7374
1990's2 (4.17)18.2507
2000's11 (22.92)29.6817
2010's24 (50.00)24.3611
2020's7 (14.58)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 24.64

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index24.64 (24.57)
Research Supply Index3.95 (2.92)
Research Growth Index5.26 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (24.64)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews7 (13.73%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other44 (86.27%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]